(2R,5S)-Ritlecitinib

(2R,5S)-Ritlecitinib

• CAS Number: 1792180-79-0
• UNSPSC Description: (2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective JAK3 inhibitor (IC50=144.8 nM) extracted from patent US20150158864A1, example 68[1].
• Target Antigen: JAK
• Type: Reference compound
• Related Pathways: Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/2r-5s-ritlecitinib.html
• Purity: 99.77
• Solubility: DMSO : ≥ 100 mg/mL
• Smiles: C[C@@H]1CC[C@@H](CN1C(C=C)=O)NC2=C3C=CNC3=NC=N2
• Molecular Weight: 285.351
• References & Citations: [1]Atli Thorarensen, et al. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyr-rolo[2,3-d]pyridinyl acrylamides. US20150158864A1.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, protect from light)
• Clinical Information: No Development Reported